MX2020009991A - Metodos basados en anticuerpos para detectar y tratar la enfermedad de alzheimer. - Google Patents
Metodos basados en anticuerpos para detectar y tratar la enfermedad de alzheimer.Info
- Publication number
- MX2020009991A MX2020009991A MX2020009991A MX2020009991A MX2020009991A MX 2020009991 A MX2020009991 A MX 2020009991A MX 2020009991 A MX2020009991 A MX 2020009991A MX 2020009991 A MX2020009991 A MX 2020009991A MX 2020009991 A MX2020009991 A MX 2020009991A
- Authority
- MX
- Mexico
- Prior art keywords
- disease
- antibody
- detecting
- based methods
- treating alzheimer
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Public Health (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862649208P | 2018-03-28 | 2018-03-28 | |
| US201862664662P | 2018-04-30 | 2018-04-30 | |
| US201862703299P | 2018-07-25 | 2018-07-25 | |
| PCT/IB2019/000358 WO2019186276A2 (en) | 2018-03-28 | 2019-03-27 | Antibody-based methods of detecting and treating alzheimer's disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020009991A true MX2020009991A (es) | 2020-10-14 |
Family
ID=66999856
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020009991A MX2020009991A (es) | 2018-03-28 | 2019-03-27 | Metodos basados en anticuerpos para detectar y tratar la enfermedad de alzheimer. |
Country Status (12)
| Country | Link |
|---|---|
| EP (1) | EP3774887A2 (https=) |
| JP (1) | JP2021520777A (https=) |
| KR (1) | KR20200144551A (https=) |
| CN (1) | CN112236452A (https=) |
| AU (1) | AU2019244481A1 (https=) |
| BR (1) | BR112020018868A2 (https=) |
| CA (1) | CA3095443A1 (https=) |
| IL (1) | IL277577A (https=) |
| MX (1) | MX2020009991A (https=) |
| RU (1) | RU2020135052A (https=) |
| SG (1) | SG11202008098TA (https=) |
| WO (1) | WO2019186276A2 (https=) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2902026C (en) | 2013-03-13 | 2023-08-29 | Prothena Biosciences Limited | Tau immunotherapy |
| CA3022515A1 (en) | 2016-05-02 | 2017-11-09 | Prothena Biosciences Limited | Antibodies recognizing tau |
| EP3452507B1 (en) | 2016-05-02 | 2022-10-19 | Prothena Biosciences Limited | Tau immunotherapy |
| CN110881274B (zh) | 2017-05-02 | 2024-11-15 | 普罗塞纳生物科学有限公司 | 识别tau的抗体 |
| AU2018308088B2 (en) | 2017-07-25 | 2025-05-29 | Truebinding, Inc. | Treating cancer by blocking the interaction of TIM-3 and its ligand |
| AU2020214796A1 (en) | 2019-01-30 | 2021-07-29 | Truebinding, Inc. | Anti-Gal3 antibodies and uses thereof |
| EP3935083A4 (en) | 2019-03-03 | 2022-11-30 | Prothena Biosciences Limited | Antibodies recognizing tau |
| EP4028040A2 (en) | 2019-09-09 | 2022-07-20 | Axon Neuroscience SE | Biomarkers and treatments of alzheimer's disease and mild cognitive impairment |
| WO2021242776A2 (en) | 2020-05-26 | 2021-12-02 | Truebinding, Inc. | Methods of treating inflammatory diseases by blocking galectin-3 |
| EP4263599A1 (en) * | 2020-12-16 | 2023-10-25 | Voyager Therapeutics, Inc. | Tau binding compounds |
| WO2022176959A1 (en) * | 2021-02-19 | 2022-08-25 | Eisai R&D Management Co., Ltd. | Anti-pt217 tau antibody |
| CN117460954A (zh) * | 2021-03-31 | 2024-01-26 | 华盛顿大学 | 作为tau蛋白病的生物标志物的CSF磷酸化tau和β-淀粉样蛋白概况 |
| CN117003863A (zh) * | 2022-04-28 | 2023-11-07 | 厦门大学 | 针对p-tau 217的抗体及其用途 |
| CN114778856B (zh) * | 2022-05-30 | 2023-03-17 | 苏州宇测生物科技有限公司 | 磷酸化tau蛋白检测试剂盒 |
| CN115078736B (zh) * | 2022-06-24 | 2025-03-25 | 佛山市观迪医疗器械有限公司 | 一种用于阿尔茨海默症的均相免疫检测试剂盒 |
| CN119836437A (zh) * | 2022-08-19 | 2025-04-15 | 舒泰神(加州)生物科技有限公司 | 特异性识别程序性细胞死亡1配体1的抗体及其用途 |
| CN117624351B (zh) * | 2023-11-24 | 2024-07-05 | 无锡傲锐东源生物科技有限公司 | 一种抗人磷酸化tau181兔单克隆抗体及其应用 |
| CN120118184A (zh) * | 2023-12-08 | 2025-06-10 | 深圳湾实验室 | 靶向Tau的特异性结合蛋白及其应用 |
| WO2025160022A1 (en) * | 2024-01-26 | 2025-07-31 | Beckman Coulter, Inc. | Detecting phosphorylated tau (p-tau) 217 using chemiluminescent dioxetane compounds |
| CN119334929B (zh) * | 2024-11-19 | 2026-02-24 | 中元汇吉生物技术股份有限公司 | 一种提升磷酸化tau蛋白检测灵敏度的方法及其试剂盒 |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4880935A (en) | 1986-07-11 | 1989-11-14 | Icrf (Patents) Limited | Heterobifunctional linking agents derived from N-succinimido-dithio-alpha methyl-methylene-benzoates |
| WO1988007089A1 (en) | 1987-03-18 | 1988-09-22 | Medical Research Council | Altered antibodies |
| US5202238A (en) | 1987-10-27 | 1993-04-13 | Oncogen | Production of chimeric antibodies by homologous recombination |
| US5204244A (en) | 1987-10-27 | 1993-04-20 | Oncogen | Production of chimeric antibodies by homologous recombination |
| IL106992A (en) | 1988-02-11 | 1994-06-24 | Bristol Myers Squibb Co | Acylhydrazone derivatives of anthracycline and methods for their preparation |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| US5112596A (en) | 1990-04-23 | 1992-05-12 | Alkermes, Inc. | Method for increasing blood-brain barrier permeability by administering a bradykinin agonist of blood-brain barrier permeability |
| US5268164A (en) | 1990-04-23 | 1993-12-07 | Alkermes, Inc. | Increasing blood-brain barrier permeability with permeabilizer peptides |
| US6797492B2 (en) | 1991-05-17 | 2004-09-28 | Merck & Co., Inc. | Method for reducing the immunogenicity of antibody variable domains |
| US5262522A (en) | 1991-11-22 | 1993-11-16 | Immunex Corporation | Receptor for oncostatin M and leukemia inhibitory factor |
| US5622929A (en) | 1992-01-23 | 1997-04-22 | Bristol-Myers Squibb Company | Thioether conjugates |
| ATE191853T1 (de) | 1992-07-27 | 2000-05-15 | Us Health | Zielgerichte liposome zur blut-hirne schranke |
| US6214345B1 (en) | 1993-05-14 | 2001-04-10 | Bristol-Myers Squibb Co. | Lysosomal enzyme-cleavable antitumor drug conjugates |
| US5457035A (en) | 1993-07-23 | 1995-10-10 | Immunex Corporation | Cytokine which is a ligand for OX40 |
| CU22615A1 (es) | 1994-06-30 | 2000-02-10 | Centro Inmunologia Molecular | Procedimiento de obtención de anticuerpos monoclonales murinos menos inmunogénicos. anticuerpos monoclonales obtenidos |
| CA2226575C (en) | 1995-07-27 | 2011-10-18 | Genentech, Inc. | Stabile isotonic lyophilized protein formulation |
| ATE234635T1 (de) | 1995-12-22 | 2003-04-15 | Bristol Myers Squibb Co | Verzweigte hydrazongruppen enthaltende kuppler |
| WO1998022120A1 (en) * | 1996-11-19 | 1998-05-28 | The Wistar Institute Of Anatomy & Biology | Diagnostic and therapeutic reagents for alzheimer's disease |
| WO1998052976A1 (en) | 1997-05-21 | 1998-11-26 | Biovation Limited | Method for the production of non-immunogenic proteins |
| US6514221B2 (en) | 2000-07-27 | 2003-02-04 | Brigham And Women's Hospital, Inc. | Blood-brain barrier opening |
| US20030083299A1 (en) | 2000-11-04 | 2003-05-01 | Ferguson Ian A. | Non-invasive delivery of polypeptides through the blood-brain barrier |
| DE10121982B4 (de) | 2001-05-05 | 2008-01-24 | Lts Lohmann Therapie-Systeme Ag | Nanopartikel aus Protein mit gekoppeltem Apolipoprotein E zur Überwindung der Blut-Hirn-Schranke und Verfahren zu ihrer Herstellung |
| CN100572392C (zh) | 2002-07-12 | 2009-12-23 | 阿克松神经科学研究和发展股份有限公司 | 截短tau蛋白 |
| CN101284136A (zh) | 2002-12-03 | 2008-10-15 | 布朗歇特洛克菲勒神经科学研究所 | 传输物质穿过血脑屏障的人工低密度脂蛋白载体 |
| EP1585520A1 (en) | 2002-12-24 | 2005-10-19 | Neurochem (International) Limited | Therapeutic formulations for the treatment of beta-amyloid related diseases |
| US7498298B2 (en) | 2003-11-06 | 2009-03-03 | Seattle Genetics, Inc. | Monomethylvaline compounds capable of conjugation to ligands |
| KR101270829B1 (ko) | 2004-09-23 | 2013-06-07 | 제넨테크, 인크. | 시스테인 유전자조작 항체 및 접합체 |
| US8012936B2 (en) | 2006-03-29 | 2011-09-06 | New York University | Tau fragments for immunotherapy |
| WO2008140639A2 (en) * | 2007-02-08 | 2008-11-20 | Oligomerix, Inc. | Biomarkers and assays for alzheimer's disease |
| US8093018B2 (en) * | 2008-05-20 | 2012-01-10 | Otsuka Pharmaceutical Co., Ltd. | Antibody identifying an antigen-bound antibody and an antigen-unbound antibody, and method for preparing the same |
| JP5599454B2 (ja) * | 2009-08-06 | 2014-10-01 | イムナス・ファーマ株式会社 | Ａβオリゴマーに特異的に結合する抗体およびその利用 |
| ES2656442T3 (es) * | 2011-09-19 | 2018-02-27 | Axon Neuroscience Se | Terapia basada en proteínas y diagnóstico de una patología mediada por tau en la enfermedad de Alzheimer |
| US9371376B2 (en) * | 2011-12-20 | 2016-06-21 | Janssen Biotech, Inc. | Anti-PHF-tau antibodies and their uses |
| US8853505B2 (en) * | 2012-02-27 | 2014-10-07 | Syngenta Participations Ag | Variety corn line AA2205 |
| US8980270B2 (en) * | 2013-01-18 | 2015-03-17 | Ipierian, Inc. | Methods of treating a tauopathy |
| SI3221349T1 (sl) * | 2014-11-19 | 2021-02-26 | Axon Neuroscience Se | Humanizirano tau protitelo pri alzheimerjevi bolezni |
| EP3412688A4 (en) * | 2016-02-05 | 2019-12-04 | Jiangsu Hengrui Medicine Co., Ltd. | THROMBIN ANTIBODY, ANTIGENBINDING FRAGMENT, AND PHARMACEUTICAL USE THEREOF |
-
2019
- 2019-03-27 WO PCT/IB2019/000358 patent/WO2019186276A2/en not_active Ceased
- 2019-03-27 RU RU2020135052A patent/RU2020135052A/ru unknown
- 2019-03-27 BR BR112020018868-9A patent/BR112020018868A2/pt not_active IP Right Cessation
- 2019-03-27 CA CA3095443A patent/CA3095443A1/en active Pending
- 2019-03-27 JP JP2020551506A patent/JP2021520777A/ja active Pending
- 2019-03-27 KR KR1020207030584A patent/KR20200144551A/ko not_active Withdrawn
- 2019-03-27 SG SG11202008098TA patent/SG11202008098TA/en unknown
- 2019-03-27 CN CN201980029711.2A patent/CN112236452A/zh active Pending
- 2019-03-27 EP EP19732436.1A patent/EP3774887A2/en not_active Withdrawn
- 2019-03-27 MX MX2020009991A patent/MX2020009991A/es unknown
- 2019-03-27 AU AU2019244481A patent/AU2019244481A1/en not_active Abandoned
-
2020
- 2020-09-24 IL IL277577A patent/IL277577A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP3774887A2 (en) | 2021-02-17 |
| KR20200144551A (ko) | 2020-12-29 |
| CN112236452A (zh) | 2021-01-15 |
| IL277577A (en) | 2020-11-30 |
| AU2019244481A1 (en) | 2020-10-01 |
| WO2019186276A8 (en) | 2020-10-15 |
| WO2019186276A2 (en) | 2019-10-03 |
| SG11202008098TA (en) | 2020-10-29 |
| RU2020135052A (ru) | 2022-04-29 |
| JP2021520777A (ja) | 2021-08-26 |
| BR112020018868A2 (pt) | 2021-01-26 |
| CA3095443A1 (en) | 2019-10-03 |
| WO2019186276A3 (en) | 2020-02-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2020009991A (es) | Metodos basados en anticuerpos para detectar y tratar la enfermedad de alzheimer. | |
| CY1125011T1 (el) | Ενεργοποιουμενα αντισωματα enanti-cd71 και μεθοδοι χρησης αυτων | |
| CO2019008786A2 (es) | Anticuerpo humanizado para tratar o prevenir trastornos cognitivos, proceso para producirlo, y agente para tratar o prevenir trastornos cognitivos usándolo | |
| CY1122245T1 (el) | Pd-1 αντισωμα, θραυσμα δεσμευσης αντιγονου αυτου, και ιατρικη εφαρμογη αυτου | |
| ECSP18005520A (es) | Anticuerpos de factor xi y métodos de uso | |
| BR112022002837A2 (pt) | Anticorpo anti-vd1 ou fragmento do mesmo, anticorpo multiespecífico isolado ou fragmento do mesmo, anticorpo humano e anticorpo multiespecífico isolado humano ou fragmento do mesmo | |
| CL2018001175A1 (es) | Anticuerpos anti-il1rap, moleculas de union de antigenos bioespecificos que unen il1rap y cd3 y usos de los mismos. | |
| BR112016030183A2 (pt) | anticorpos e fragmentos de ligação ao antígeno que se ligam especificamente à proteína tau associada a microtúbulos | |
| MX2018000505A (es) | Anticuerpos especificos para tau hiperfosforilada y metodos de uso de los mismos. | |
| EA202091810A1 (ru) | Антитела к b7-h4 и способы их применения | |
| AR110114A1 (es) | ANTICUERPOS CONTRA b-AMILOIDE PIROGLUTAMATO Y SUS USOS | |
| MX388142B (es) | Anticuerpos tau humanizados en enfermedad de alzheimer. | |
| JOP20210166A1 (ar) | علاج الصداع الناتج عن فرط استعمال الأدوية باستخدام أجسام مضادة لـcgrp أو أجسام مضادة لـcgrp-r | |
| CO2019007686A2 (es) | Anticuerpos anti-properdina monovalentes y fragmentos de anticuerpo | |
| CO2021011944A2 (es) | Anticuerpos de cd33 y métodos para usar los mismos para tratar el cáncer | |
| EA201891388A1 (ru) | Ингибиторы калликреина плазмы и их применение для лечения обострения наследственного ангионевротического отека | |
| EA202191666A1 (ru) | Антитела к il-27 и их применение | |
| CL2017001756A1 (es) | Régimen de dosificación para antagonistas de madcam. | |
| EA201892284A1 (ru) | Комбинация антитела против cd20, селективного ингибитора pi3-киназы-дельта и ингибитора btk для лечения b-клеточных пролиферативных расстройств | |
| CL2019003485A1 (es) | Métodos para redicur la proteinuria en un sujeto humano que padece de nefropatía por inmunoglobulina a. (divisional solicitud 201900909) | |
| BR112018014762A2 (pt) | método de tratamento da doença de alzheimer (da) precoce | |
| EA201990895A1 (ru) | Антитела к о1 и варианты их применения | |
| CL2025000063A1 (es) | Anticuerpos anti-abeta | |
| BR112022026533A2 (pt) | Anticorpo anti-fxi/fxia, fragmento de ligação do mesmo, e antígenos e uso farmacêutico do mesmo | |
| MX2022004049A (es) | Tratamiento basado en biomarcadores de la glomeruloesclerosis focal y segmentaria y de la enfermedad renal diabetica. |